Hermab 440 Mg

About Hermab 440 Mg

Hermab 440 mg contains Trastuzumab, which is a monoclonal antibody used in the treatment of HER2-positive cancers, primarily HER2-positive breast cancer and HER2-positive gastric cancer. Trastuzumab works by targeting and inhibiting the activity of the HER2 receptor, a protein that promotes cancer cell growth when overexpressed.

Indications

Trastuzumab (Hermab) is used for:

• HER2-positive breast cancer: Trastuzumab is indicated for the treatment of both early-stage and metastatic (advanced) breast cancer that tests positive for HER2 overexpression.
• HER2-positive gastric cancer: It is also used for the treatment of HER2-positive gastric or gastroesophageal junction adenocarcinoma, particularly in advanced stages or when the cancer has spread to other parts of the body.

Mechanism of Action

Trastuzumab binds to the HER2 receptor on the surface of cancer cells, blocking the receptor's ability to send signals that promote cell growth. This results in inhibition of cancer cell proliferation. Trastuzumab also helps the immune system recognize and destroy cancer cells by promoting antibody-dependent cellular cytotoxicity (ADCC).

Dosage and Administration

• Typical Dosage: The dose of Trastuzumab (Hermab) is usually determined based on the patient's body surface area. The initial dose for HER2-positive breast cancer or gastric cancer is typically 8 mg/kg as an intravenous infusion. Subsequent maintenance doses are usually 6 mg/kg every 3 weeks.

  • Breast Cancer: Often administered every 3 weeks in combination with chemotherapy for metastatic or early-stage HER2-positive breast cancer.
  • Gastric Cancer: The typical dose for gastric cancer is also 8 mg/kg for the initial dose, followed by 6 mg/kg every 3 weeks.

• Administration: Trastuzumab is given intravenously (IV) and is usually administered in a healthcare setting, such as a hospital or clinic. It is important to monitor for infusion reactions during the first few doses.

Side Effects

Common side effects of Trastuzumab include:

• Infusion-related reactions: These can include fever, chills, nausea, vomiting, headache, or difficulty breathing, particularly during the first infusion.
• Fatigue: Feeling tired or weak is common during treatment.
• Nausea and vomiting
• Musculoskeletal pain: Joint pain or muscle aches can occur.

Serious side effects can include:

• Heart problems: Trastuzumab can lead to heart failure or other cardiac issues, particularly in patients with pre-existing heart conditions. Cardiac monitoring is often recommended, including echocardiograms or ejection fraction tests to assess heart function.
• Lung toxicity: In some cases, Trastuzumab may lead to lung problems, including interstitial lung disease.
• Increased risk of infections: As a monoclonal antibody that targets the immune system, it may make patients more susceptible to infections.

Precautions and Warnings

• Cardiac monitoring: Because Trastuzumab can affect the heart, patients must be closely monitored for any signs of heart failure. This is especially important for patients with a history of heart disease or for those receiving other chemotherapy drugs that can affect the heart.
• Infusion reactions: Trastuzumab can cause allergic reactions during the infusion process. This is more likely to happen with the first few doses, so patients are monitored for these reactions during the infusion.
• Pregnancy and breastfeeding: Trastuzumab is contraindicated during pregnancy, as it can harm the fetus. It should also not be used during breastfeeding, as it can be passed through breast milk.
• Liver function: Liver enzyme levels should be monitored, as Trastuzumab can affect liver function in some patients.

Important Considerations

• Resistance: In some cases, cancer cells may become resistant to Trastuzumab after prolonged treatment. If resistance occurs, alternative therapies may be required.
• Long-term use: Trastuzumab is often used as part of a longer-term treatment plan, sometimes in combination with other chemotherapy drugs. Regular follow-ups and monitoring are necessary.

Conclusion

Hermab (Trastuzumab) is an essential therapy for HER2-positive cancers, especially breast cancer and gastric cancer, significantly improving survival rates. However, it requires careful monitoring, particularly for cardiac and infusion-related issues. With appropriate supervision and management of side effects, Trastuzumab can be an effective part of cancer treatment.

Precision Oncology with Hermab

Hermab 440 mg offers targeted therapy for HER2-positive breast and gastric cancer patients. Utilizing monoclonal antibody technology, it precisely blocks HER2 receptors found in certain cancer cells, helping to halt disease progression. This tailored approach ensures that only relevant cells are targeted, minimizing impacts on healthy tissue.


Safe and Simple Preparation

Hermab is supplied as a ready-to-reconstitute lyophilized powder with an included sterilized solvent vial. Medical professionals can easily prepare the intravenous solution manually, ensuring accurate dosing and pharmaceutical quality. Its compact vial makes it practical for clinics, hospitals, and pharmacies.


Strict Quality and Storage

Manufactured to high pharmaceutical standards in India, Hermab maintains efficacy and safety for up to 24 months when stored at 2C-8C. The vial and included solvent are clearly labeled and conveniently packaged for easy handling while ensuring patient safety.